Krystal Biotech (NASDAQ:KRYS) Insider Sells $7,702,750.00 in Stock

Posted by Brenda Bartman on Jun 5th, 2026

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider directly owned 1,378,155 shares in the company, valued at approximately $424,623,337.05. This trade represents a 1.78% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Trading Down 2.2%

KRYS traded down $6.79 during trading on Friday, reaching $301.00. 264,305 shares of the company were exchanged, compared to its average volume of 291,307. Krystal Biotech, Inc. has a 52 week low of $127.99 and a 52 week high of $319.48. The firm has a 50 day moving average of $281.47 and a 200 day moving average of $263.93. The stock has a market cap of $8.87 billion, a P/E ratio of 40.24 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS – Get Free Report) last announced its quarterly earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.45 by $0.38. The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. As a group, analysts forecast that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have commented on KRYS shares. Zacks Research cut shares of Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research report on Thursday, February 5th. Wolfe Research began coverage on Krystal Biotech in a research report on Friday, March 27th. They set a “peer perform” rating for the company. Citigroup increased their price objective on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a report on Tuesday, May 5th. Evercore restated an “outperform” rating and issued a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Chardan Capital lifted their target price on Krystal Biotech from $220.00 to $323.00 and gave the company a “buy” rating in a research note on Wednesday, February 18th. Ten research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $324.11.

View Our Latest Stock Report on Krystal Biotech

Hedge Funds Weigh In On Krystal Biotech

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Seven Fleet Capital Management LP increased its position in shares of Krystal Biotech by 7.9% during the 1st quarter. Seven Fleet Capital Management LP now owns 4,316 shares of the company’s stock valued at $1,115,000 after purchasing an additional 316 shares during the period. Western Wealth Management LLC acquired a new stake in shares of Krystal Biotech in the first quarter valued at $34,000. Bank of America Corp DE lifted its holdings in shares of Krystal Biotech by 36.6% in the first quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock valued at $67,330,000 after buying an additional 69,840 shares during the period. Janus Henderson Group PLC boosted its stake in Krystal Biotech by 21.5% during the first quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock valued at $68,879,000 after buying an additional 47,219 shares in the last quarter. Finally, Cim LLC acquired a new position in Krystal Biotech during the first quarter worth about $3,872,000. 86.29% of the stock is owned by institutional investors.

About Krystal Biotech

(Get Free Report)

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.